Wednesday, January 4, 2017

BRIEF-Aevi Genomic Medicine top-line results for Phase 2/3 SAGA clinical trial expected in Q1 2017

* Aevi Genomic Medicine announces completion of enrollment

for Phase 2/3 SAGA clinical trial of AEVI-001 (NFC-1) in MGLUR+

ADHD adolescents

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)